找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Gastrointestinal Stromal Tumor; Research and Practic Yukinori Kurokawa,Yoshito Komatsu Book 2019 Springer Nature Singapore Pte Ltd. 2019 Ga

[复制链接]
查看: 30931|回复: 50
发表于 2025-3-21 18:54:16 | 显示全部楼层 |阅读模式
书目名称Gastrointestinal Stromal Tumor
副标题Research and Practic
编辑Yukinori Kurokawa,Yoshito Komatsu
视频video
概述Enriches our understanding of GISTs both from basic to clinical aspects.Collects unique and cutting-edge data from the Asian region.Provides a comprehensive update of GISTs
图书封面Titlebook: Gastrointestinal Stromal Tumor; Research and Practic Yukinori Kurokawa,Yoshito Komatsu Book 2019 Springer Nature Singapore Pte Ltd. 2019 Ga
描述This book provides a comprehensive and up-to-date overview of gastrointestinal stromal tumors (GISTs)...GISTs represent the most common mesenchymal neoplasms arising within the gastrointestinal tract. The causative gene of this disease was originally discovered in Japan by Prof. Seichi Hirota in 1998, and since then numerous important advances – from basic to clinical aspects – have been reported from Japan. Professionals involved in the management of GISTs inevitably cite significant evidence and the state-of-the-art treatments from the Asian region, where has there is and inherently high prevalence of gastrointestinal cancers..Each expert author elucidates the cutting-edge knowledge on pathophysiology, diagnosis, and treatment of GISTs, especially focusing on the highly valuable data from Japan. This attractive collection benefits not only oncologists but also basic researchers, general physicians and surgeons, as well as paramedical staff and medical students who aredealing with GISTs..
出版日期Book 2019
关键词Gastrointestinal cancer; Gastrointestinal tract; Mesenchymal neoplasm; Imatinib; Malignancy; surgical onc
版次1
doihttps://doi.org/10.1007/978-981-13-3206-7
isbn_ebook978-981-13-3206-7
copyrightSpringer Nature Singapore Pte Ltd. 2019
The information of publication is updating

书目名称Gastrointestinal Stromal Tumor影响因子(影响力)




书目名称Gastrointestinal Stromal Tumor影响因子(影响力)学科排名




书目名称Gastrointestinal Stromal Tumor网络公开度




书目名称Gastrointestinal Stromal Tumor网络公开度学科排名




书目名称Gastrointestinal Stromal Tumor被引频次




书目名称Gastrointestinal Stromal Tumor被引频次学科排名




书目名称Gastrointestinal Stromal Tumor年度引用




书目名称Gastrointestinal Stromal Tumor年度引用学科排名




书目名称Gastrointestinal Stromal Tumor读者反馈




书目名称Gastrointestinal Stromal Tumor读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

1票 100.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 23:39:21 | 显示全部楼层
发表于 2025-3-22 03:09:04 | 显示全部楼层
Book 2019oplasms arising within the gastrointestinal tract. The causative gene of this disease was originally discovered in Japan by Prof. Seichi Hirota in 1998, and since then numerous important advances – from basic to clinical aspects – have been reported from Japan. Professionals involved in the manageme
发表于 2025-3-22 05:58:38 | 显示全部楼层
https://doi.org/10.1007/978-3-662-00599-6red as at least some malignancy (labeled as /1 or /3 in the behavior code of ICD-O-3). We do not know how many cases are there that are considered as benign. Some summaries of the current status of GIST treatment are provided using the same dataset.
发表于 2025-3-22 09:24:19 | 显示全部楼层
,Modellrechnung zur Chemie der Atmosphäre,n is recommended for imatinib-resistant GISTs. Regorafenib should be considered in patients with imatinib or sunitinib-resistant GISTs. During these tyrosine kinase therapies, surgery should be considered if feasible.
发表于 2025-3-22 16:38:48 | 显示全部楼层
Epidemiology,red as at least some malignancy (labeled as /1 or /3 in the behavior code of ICD-O-3). We do not know how many cases are there that are considered as benign. Some summaries of the current status of GIST treatment are provided using the same dataset.
发表于 2025-3-22 18:51:50 | 显示全部楼层
Treatment Guidelines,n is recommended for imatinib-resistant GISTs. Regorafenib should be considered in patients with imatinib or sunitinib-resistant GISTs. During these tyrosine kinase therapies, surgery should be considered if feasible.
发表于 2025-3-22 22:25:58 | 显示全部楼层
发表于 2025-3-23 03:56:24 | 显示全部楼层
First-Line Treatment,ct of imatinib is the trough level of imatinib. Although the treatment results improved, primary resistant cases, in which the effect of imatinib cannot be expected from the beginning, and secondary resistant cases, in which the effect was exhibited at the beginning but resistance was exhibited later, have become problematic.
发表于 2025-3-23 09:03:19 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-22 18:48
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表